CC
ACRS icon

Checkpoint Capital’s Aclaris Therapeutics ACRS Stock Holding History

Checkpoint Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-453,614
Closed -$476K – 18
2023
Q4 		$476K Buy
+453,614
New +$1.38M 0.29% 18

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Checkpoint Capital's ACRS Position: Q1 2024 in Review

Checkpoint Capital sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 453,614 shares — an estimated $476K sold.

Checkpoint Capital first reported a position in ACRS in Q4 2023 and held it in 1 quarter. The position peaked at $476K in Q4 2023. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

  • Checkpoint Capital reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Checkpoint Capital sold 453,614 Aclaris Therapeutics shares in Q1 2024, an estimated $476K.
  • Checkpoint Capital first reported a position in Aclaris Therapeutics in Q4 2023 and held it in 1 quarter.
  • Checkpoint Capital's Aclaris Therapeutics position peaked at $476K in Q4 2023.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on Checkpoint Capital's 13F filing for Q1 2024, filed 15 May 2024.